CVRF
  • Login
  • Register
  • CVRF's Meetings
    TCTAP AP VALVES & SH COMPLEX PCI

SummitMD SummitMD

TCTAP 2023
  • Home
  • News
    • SummitMD News
    • Conference News
      • TCTAP
      • AP VALVES & SH
      • COMPLEX PCI
      • ACT PROGRAM
  • Videos
    • TCTAP
    • AP VALVES & SH
    • COMPLEX PCI
    • ACT PROGRAM
  • Slides
    • Coronary
    • Endovascular
    • Structural Heart Disease
    • Valve
    • Imaging & Physiology
    • Pharmacology
  • Book
  • Conferences
    • TCTAP
    • AP VALVES & STRUCTURAL HEART
    • COMPLEX PCI
  • About CVRF
    • Mission
    • Board Members
    • R&D Divisions
      • Clinical Research Coordinating Center
      • Translational Research Center
      • Research Activity
      • Paper Publication
    • Education
      • ACT Program
      • Website

Presenter's Information

  • Home
  • Slides

Matthew Price, MD

Country USA
Specialty Interventional Cardiologist
  • Slide Presentations
  1. [Platelet Function Tests-Buckling the Belief] For: Tailored Therapy, Frustrated but Not Gone
  2. [Is Left Appendage Closure an Alternative ?] For: YES! Safe and Effective
  3. [Is Left Appendage Closure an Alternative ?] Case Presentation: Best and Worse Cases of LAA Closure
  4. Structural Heart Disease 2013: LAA Closure and TAVR for Extreme and High Risk Patients
  5. Featured Lecture: The Future Is¡¦ New Anti-platelet Agents (Ticagrelor/Prasugrel), Selective Platelet Function Testing, and Patient-specific DAPT Duration (from 3 Months to Indefinite)
  6. Requirements for a Successful LAAC Program
  7. How to Overcome the Challenges?: Double the Dose?
  8. The Landscape of Antiplatelet Agents: Which Drug, for Whom, and Why?
  9. Standard vs. High-Dose Clopidogrel According to Platelet Function Testing after PCI: Results of the GRAVITAS Trial
  10. Interventional Pharmacology
  11. Clopidogrel Use in ACS and PCI (CURRENT-OASIS 7, Genetic Resistance Studies, GRAVITAS, CLARITY-TIMI 28, and PPI & DAT for ACS; VA Registry, PRINCIPLE, TRITON-TIMI 38, COGENT, and FAMOUS)
  12. Cilostazol: Triple Benefits - More Is Better
  13. Ticagrelor: PLATO - A New Chapters Opens
  14. Does the Efficacy of Bivalirudin During PCI Depend on Clopidogrel Pretreatment?
  15. Definitely: The Data Are Strong
  16. Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?
Conference Slides
  • TCTAP
  • AP VALVES & SH
  • COMPLEX PCI
Category

Coronary

  • Left Main
  • Bifurcation
  • CTO
  • Long Lesion
  • Ostial
  • In-stent Restenosis
  • Others

Endovascular

  • Carotid
  • Peripheral Disease
    • SFA
    • BTK
    • Iliac
    • Poplitial
    • Subclavian
  • Abdominal Aorta
  • Renal
  • Others

Structural Heart Disease

  • Congenital Heart Disease
  • HOCM
  • Others

Valve

  • TAVR
  • Others

Imaging & Physiology

  • Antiplatelet
  • Anticoagulant
  • Lipid and Inflammation
  • Others

Pharmacology

  • Antiplatelet
  • Anticoagulant
  • Lipid and Inflammation
  • Others

  • Upcoming Events
  • 28th
    TCTAP 2023
    May 6-9, 2023
    Grand Walkerhill Seoul, Korea
  • 12th
    AP VALVES & SH 2023
    August 10-11, 2023
    Grand Walkerhill Seoul, Korea
  • 8th
    COMPLEX PCI 2023
    November 23-24, 2023
    Grand Walkerhill Seoul, Korea
CVRF
CardioVascular Research Foundation
Àç´Ü¹ýÀÎ ½ÉÀåÇ÷°ü¿¬±¸Àç´Ü
2F Asan Institute for Education & Research
88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul 05505, Korea
´ëÇ¥ÀÚ: ¹Ú½ÂÁ¤ | ÀüÈ­¹øÈ£: 02-3010-4720
»ç¾÷ÀÚµî·Ï¹øÈ£: 215-82-06387

Privacy Policy

The Latest News
  • Extended BEST trial offers insight into murky dispute over optimal long-term revasc strategy in MVCAD
    23-01-06
  • TAVI noninferior to surgery for elderly, severe AS patients at moderate operative risk: UK TAVI
    22-10-14
  • [DOWNLOAD FREE EBOOK] Technical Forum A to Z: Complex Coronary Intervention - 3rd Edition
    22-10-7
Porto Website Template

Copyright 2002. All Rights Reserved.